Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Biopharma M&A in 2023 navigates shifting climate with calculated bets on de-risked targets

By Brian Buntz | October 31, 2023

Puzzle, business hands and group of people for solution, teamwork and goals, integration or workflow success. Team building, games and development of person problem solving, synergy or collaboration.

[See Less/Adobe Stock]

2023 biopharma M&A trends

M&A activity has rebounded to a degree in 2022 and 2023, but deal-making is still below some of the top years in recent decades, including 2011, 2014, and 2015. While M&A remains a fact of life in biopharma, buyers are selective about disease focus areas. Oncology, immunology and obesity/cardiometabolic therapies are a focus of many recent deals. Similarly, recent acquisitions tend to focus on de-risked targets in phase 3 or already on the market, reflecting acquirers’ risk aversion.

Despite increasing interest rates and FTC scrutiny, biopharma M&A activity remains resilient. “I do think that the market is remaining consistent,” said Rebecca A. Guzman, a partner at Duane Morris LLP. Guzman serves as a vice chair of the M&A division at the firm. “The regulatory landscape is obviously changing, and it’s something we’re continuing to watch. But I don’t foresee it necessarily having an impact on people’s strategy of continuing to build their pipeline.”

A buyer’s market

Rebecca Morris

Rebecca Guzman

With the biotech industry facing a challenging phase over the past couple of years, with an uptick in layoffs, falling stocks and shuttered companies, acquirers tend to have sway in deal-making. But investors’ willingness to invest in early-stage assets depends on their risk profile.

A significant number of Big Pharma companies have venture arms dedicated to investing in earlier stage companies, with an understanding that developing external pipelines can be more efficient than what they can achieve within their four walls. “It’s not necessarily because they aim to eventually acquire all of these companies, but rather to accelerate the market overall — a rising tide lifts all ships, so to speak,” Guzman said.

With the biotech sector facing a challenging funding environment and scant IPO opportunities, M&A is the de facto exit strategy for many biotech firms with late-stage assets. Against that backdrop, there is a surge in deal capacity, according to IQVIA, with the top 15 pharma companies having a combined deal capacity of $0.8 trillion.

On top of that, Big Pharma companies continue to grapple with patent cliffs over the next several years. “In that regard, when you have a lot of cash on hand, there are really two main things you can do: give it back to your investors or reinvest it to try to make the pie bigger,” Guzman said.

Many companies are opting for the latter, making use of their strong financial positions to acquire biotech firms with late-stage assets in competitive areas. For example, in October, Roche entered an agreement to acquire Telavant, a biotech company developing therapies for inflammatory and fibrotic diseases. Telavant’s leading investigational product, RVT-3101, is a fully human monoclonal antibody targeting TL1A, which modulates the location and severity of inflammation and fibrosis. The drug candidate offers promise for ulcerative colitis and Crohn’s disease.

Similarly, also in October, Eli Lilly announced its plans to acquire Point Biopharma, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer, for $1.4 billion.

In March, Pfizer said it plans on acquiring Seagen, a biotech company focused on developing cancer treatments, for a cool $43 billion.

More momentum to come?

Biopharma companies are increasingly looking to M&A to drive near-term revenue. As IQVIA noted, some 83% of transactions in the first half of 2023 focused on assets in phase 3 or already on the market. In addition, acquirers tend to prefer strategic bolt-on acquisitions, valued at less than $6.5 billion, over mega deals. Such deals accounted for 83% of all M&A transactions over the past five years, IQVIA reckoned.

As acquirers experiment with a more cautious and calculated M&A approach, savvy acquirers are likely to gain a competitive edge in a rapidly evolving market. Here, experienced Big Pharma companies with experience commercializing products are at an advantage. “There’s a common saying: ‘buy the approval, sell the launch,’” Guzman said.

By focusing on de-risked, phase 3 or market-ready assets, Big Pharma can ensure a quicker path to revenue generation, mitigating the risks associated with early-stage development. More M&A activity could be coming, Guzman projected: “I think it’s only a matter of time before there’s an additional uptick based on various market conditions and the ever-evolving regulatory framework,” she said. “I do think that we’re going to bounce back and that we’ll reach a point of more consistency.”


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: Biopharma M&A, Market trends in biotech, Oncology therapies, Pharmaceutical acquisitions, Phase 3 drug development, Regulatory landscape in pharma, Risk management in pharma
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE